Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PDS01ADC + enzalutamide
- Development stage
- Unknown
- Lead developer
- PDS Biotech
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
PDS01ADC + enzalutamide is a combination therapy being developed by PDS Biotech for the treatment of prostate cancer, specifically biochemically recurrent prostate cancer. PDS01ADC (also known as M9241 or NHS-IL12) is an antibody-conjugated cytokine (immunocytokine) designed to deliver interleukin-12 (IL-12) directly to the tumor microenvironment. It consists of a human monoclonal antibody (NHS76) that targets necrotic DNA in the tumor microenvironment, fused to two molecules of human IL-12. IL-12 is a potent pro-inflammatory cytokine that stimulates T-cell and natural killer (NK) cell activity. Enzalutamide is a second-generation androgen receptor inhibitor that blocks the growth of prostate cancer cells by inhibiting androgen binding, nuclear translocation, and DNA binding. The combination aims to leverage the immunomodulatory effects of IL-12 to enhance the anti-tumor activity of hormonal therapy and overcome resistance mechanisms in prostate cancer.
- Brand names
- Xtandi
- Other names
- NHS-IL12 + enzalutamide
02
Targets
Tumor-associated necrotic DNAIL-12R (Interleukin-12 receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on PDS01ADC + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PDS01ADC + enzalutamide.